Pricing
  1. JP-listed companies
  2. Carna Biosciences, Inc.
  3. Financials
  4. Gross profit

Carna Biosciences, Inc. (4572)

Market cap
¥7.4B
P/E ratio
-3.5x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndGross profit (Million JPY)YoY (%)
Dec 31, 2025388-16.65%
Dec 31, 2024466-67.90%
Dec 31, 20231,451+19.37%
Dec 31, 20221,215-35.44%
Dec 31, 20211,882+99.97%
Dec 31, 2020941-68.63%
Dec 31, 20193,000+495.21%
Dec 31, 2018504+15.86%
Dec 31, 2017435-21.92%
Dec 31, 2016557-57.13%
Dec 31, 20151,300+243.08%
Dec 31, 2014379

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat